imidazolium- bis(imidazole)tetrachlororuthenate(III)

05/01/1989 - "All compounds caused a tumor growth inhibition exceeding 90%; differences were found with regard to toxicity: ImH(RuIm2Cl4 and (BzImH)2(RuBzImCl5) caused dose-related decreases in body weight and increases in mortality as shown by 21% and 29% body weight loss compared to controls as well as 10% and 45% mortality for the two dosages of the first compound, and 9% body weight loss compared to controls as well as 7% mortality for the latter compound. "
01/01/1991 - "The comparison of the antineoplastic action of BBR2382 with that of ImH[RuIm2Cl4] is always in favor of the former, independently of the parameter chosen and of the tumor system used. "
01/01/1991 - "Antineoplastic effect of mer-trichlorobisdimethylsulphoxideaminorutheniumIII against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]."
01/01/1991 - "Qualitatively, the antitumor action of BBR2382 seems different from that of cisplatin and of ImH[RuIm2Cl4]; it is supposed that this agent, like other "rutheniumIII dimethylsulphoxide" complexes, could have a particular efficacy for tumors localized in the lungs."
10/01/1991 - "The tumor-inhibiting metal complex trans-imidazolium-bisimidazoletetrachlororuthenate(III) (ICR) reacts with DNA and inhibits template-primer properties for DNA synthesis catalysed by Escherichia coli DNA polymerase I. The reaction with DNA depends on the aging (half-life 6.8 h) of the aqueous solution containing ICR. "

05/01/1989 - "SD rats bearing acetoxymethylmethylnitrosamine-induced colorectal carcinomas were treated by i.v. administration of trans-imidazolium-bisimidazoletetrachlororuthenate (III) ImH(RuIm2Cl4), bisbenzimidazolium-benzimidazolepentachlororuthenate (III) (BzImH)2(RuBzImCl5) and trans-indazolium-bisindazoletetrachlororuthenate (III) In-dH(ruInd2Cl4). "
01/01/1987 - "The activity of the newly synthesized ruthenium derivative imidazolium-bis(imidazole)tetrachlororuthenate (III) [ImH(RuIm2Cl4)] was compared with that of 5'-deoxy-5-fluorouridine (5'dFUR) in autochthonous acetoxy-methyl-methylnitrosamine (AMMN)-induced colorectal cancer in SD rats. "

05/01/1989 - "The dose levels used were 0.022 mmol/kg body weight administered twice weekly over ten weeks for all compounds and, additionally, 0.015 mmol/kg for ImH(RuIm2Cl4). "
05/01/1989 - "All compounds caused a tumor growth inhibition exceeding 90%; differences were found with regard to toxicity: ImH(RuIm2Cl4 and (BzImH)2(RuBzImCl5) caused dose-related decreases in body weight and increases in mortality as shown by 21% and 29% body weight loss compared to controls as well as 10% and 45% mortality for the two dosages of the first compound, and 9% body weight loss compared to controls as well as 7% mortality for the latter compound. "

01/01/1987 - "ImH(RuIm2Cl4) exhibited considerable antitumoral efficacy compared with 5'dFUR (20 T/C % and 60 T/C %, respectively) against the growth of AMMN-induced colorectal adenocarcinoma in SD rats. "